Akari Therapeutics Plc
News
Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com
Ticker Report StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the...\n more…
Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
Ticker Report StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a report released on Friday morning. The firm issued a sell rating on the biopharmaceutical company's...\n more…
Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com
Zolmax StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Free Report) in a report released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company's...\n more…
Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
Ticker Report Analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX - Get Free Report) in a report released on Thursday. The firm set a "sell" rating on the biopharmaceutical...\n more…
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Globe Newswire Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology...\n more…
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Globe Newswire Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophyBOSTON and LONDON, Aug. 19, 2024 (GLOBE...\n more…